국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
Hydrochlorothiazide; Eprosartan
PCO Manufacturing Ltd.
C09DA02
Hydrochlorothiazide; Eprosartan
600 mg/12.5 milligram(s)
Film-coated tablet
eprosartan and diuretics
2019-05-24
_ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER TEVETEN ® PLUS 600 MG/12.5 MG FILM-COATED TABLETS eprosartan/hydrochlorothiazide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. The full name of your medicine is Teveten Plus 600 mg/12.5 mg film-coated tablets. In this leaflet the shorter name Teveten Plus is used. WHAT IS IN THIS LEAFLET 1. What Teveten Plus is and what it is used for 2. What you need to know before you take Teveten Plus 3. How to take Teveten Plus 4. Possible side effects 5. How to store Teveten Plus 6. Contents of the pack and other information 1. WHAT TEVETEN PLUS IS AND WHAT IT IS USED FOR Teveten Plus is used: to treat high blood pressure. Teveten Plus contains two active ingredients: eprosartan and hydrochlorothiazide. EPROSARTAN belongs to a group of medicines called “angiotensin II receptor antagonists”. It blocks the action of a substance in your body called ‘angiotensin II’. This substance causes your blood vessels to narrow. This makes it more difficult for the blood to flow through the vessels and so your blood pressure increases. By blocking this substance, the vessels relax and your blood pressure decreases. HYDROCHLOROTHIAZIDE belongs to a group of medicines called “thiazide diuretics”. It increases how often and how much urine you pass. This decreases your blood pressure. You will only be given Teveten Plus if your blood pressure is not lowered enough by eprosartan on its own. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE TEVETEN PLUS DO NOT TAKE TEVETEN PLUS IF: 전체 문서 읽기
Health Products Regulatory Authority 27 May 2019 CRN008ZV5 Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Teveten Plus 600 mg/12.5 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains eprosartan mesylate equivalent to 600 mg eprosartan and 12.5 mg hydrochlorothiazide. Excipient with known effect Lactose (as monohydrate) For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet _Product imported from Greece_ Butterscotch-coloured, capsule-shaped film-coated tablets The inscription of the tablet is "5147" on one side. 4 CLINICAL PARTICULARS As per PA2010/018/001 5 PHARMACOLOGICAL PROPERTIES As per PA2010/018/001 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS TABLET CORE: Lactose monohydrate Microcrystalline cellulose Pregelatinised starch (from maize) Crospovidone Magnesium stearate Purified water FILM COAT: Polyvinyl alcohol Talc Titanium dioxide (E171) Macrogol 3350 Iron oxide yellow (E172) Iron oxide black (E172) 6.2 INCOMPATIBILITIES Not applicable. Health Products Regulatory Authority 27 May 2019 CRN008ZV5 Page 2 of 2 6.3 SHELF LIFE The shelf-life expiry date of this product is the date shown on the blister and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE This medicinal product does not require any special storage conditions. 6.5 NATURE AND CONTENTS OF CONTAINER Blister packs of 28 tablets contained in an outer cardboard carton. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL OF A USED MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCT AND OTHER HANDLING OF THE PRODUCT No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/448/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 24 th May 2019 10 DATE OF REVISION OF THE TEXT 전체 문서 읽기